[1]赵 倩,冯 娇.肝细胞癌组织中PRDX4，GRAMD1A 水平表达与临床病理特征及预后的关系研究[J].现代检验医学杂志,2024,39(03):120-124.[doi:10.3969/j.issn.1671-7414.2024.03.020]
　ZHAO Qian,FENG Jiao.Study on the Relationship among the Expression of PRDX4 and GRAMD1A Levels in Hepatocellular Carcinoma Tissues with Clinicopathologic Features and Prognosis[J].Journal of Modern Laboratory Medicine,2024,39(03):120-124.[doi:10.3969/j.issn.1671-7414.2024.03.020]
点击复制

肝细胞癌组织中PRDX4，GRAMD1A 水平表达与临床病理特征及预后的关系研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年03期
页码:
120-124
栏目:
论著
出版日期:
2024-05-15

文章信息/Info

Title:
Study on the Relationship among the Expression of PRDX4 and GRAMD1A Levels in Hepatocellular Carcinoma Tissues with Clinicopathologic Features and Prognosis
文章编号:
1671-7414（2024）03-120-05
作者:
赵 倩; 冯 娇
（巴中市中心医院检验科，四川巴中 636600）
Author(s):
ZHAO Qian; FENG Jiao
（Department of Clinical Laboratory, Bazhong Central Hospital, Sichuan Bazhong 636600, China）
关键词:
肝细胞癌; 过氧化物还原酶4; GRAM 结构域蛋白1A
分类号:
R735.7；R730.43
DOI:
10.3969/j.issn.1671-7414.2024.03.020
文献标志码:
A
摘要:
目的 探究肝细胞癌(hepatocellular carcinoma，HCC) 组织中过氧化物还原酶4（peroxiredoxin 4，PRDX4），GRAM 结构域蛋白1A（GRAM domain-containing protein 1A，GRAMD1A）的水平表达，并分析二者与临床病理特征及预后的关系。方法 收集巴中市中心医院2017 年5 月～ 2020 年5 月收治的136 例肝细胞癌患者作为研究对象，术中取癌组织与癌旁组织，采用免疫组织化学法测定肝细胞癌组织与癌旁组织中PRDX4 和GRAMD1A 的表达，Kaplan-Meier生存曲线分析PRDX4 和GRAMD1A 表达与肝细胞癌患者生存率的关系，COX 回归模型分析肝细胞癌患者预后的影响因素。结果 肝细胞癌组织PRDX4[69.12%（94/136）] 和GRAMD1A阳性表达率［58.82%（80/136）］高于癌旁组织[7.35%（10/136），18.38%（25/136）]，差异具有统计学意义（χ2=109.846，46.923，均P ＜ 0.05）。TNM 分期为Ⅲ期+ Ⅳ期、组织分化程度低分化、肿瘤多发、HBsAg 阳性的肝细胞癌患者PRDX4 和GRAMD1A 阳性表达比例显著高于TNM 分期为Ⅰ期+ Ⅱ期、组织分化程度高/ 中分化、肿瘤少发、HBsAg 阴性的肝细胞癌患者，差异具有统计学意义（χ2=12.273，16.359，10.004，5.485；23.217，24.461，18.651，8.594，均P ＜ 0.05）；肝细胞癌组织PRDX4 阳性表达患者的三年生存率[43.62%（41/94）] 低于PRDX4 阴性表达患者[73.81%（31/42）]，肝细胞癌组织GRAMD1A 阳性表达患者三年生存率[46.25%（37/80）] 低于GRAMD1A 阴性表达患者[62.50%（35/56）]，差异具有统计学意义（χ2=12.965，7.475，均P ＜ 0.05）；TNM 分期、肿瘤数量、HBsAg，PRDX4 和GRAMD1A 表达是影响肝细胞癌患者死亡的独立危险因素（均P ＜ 0.05）。结论 肝细胞癌组织中PRDX4 和GRAMD1A 阳性率升高，与患者预后不良密切相关，二者可作为肝细胞癌诊断和预后评估的生物标记物。
Abstract:
Objective To investigate the expression of peroxiredoxin 4 (PRDX4) and GRAM domain-containing protein 1A (GRAMD1A) levels in hepatocellular carcinoma（HCC）tissue and analyze their relationship with clinical pathological characteristics and prognosis. Methods A total of 136 patients with HCC admitted to Bazhong Central Hospital from May 2017 to May 2020 were regarded as research subjects. Cancer tissue and adjacent tissue were taken during surgery. Immunohistochemical method was applied to determine the expression of PRDX4 and GRAMD1A in HCC tissues and adjacent tissues. Kaplan-Meier survival curve was applied to analyze the relationship between PRDX4 and GRAMD1A expression and survival rate in HCC patients. COX regression model was applied to analyze the prognostic factors of HCC patients. Results The positive expression rates of PRDX4 [69.12% (94/136) ] and GRAMD1A [58.82% (80/136)] in HCC tissues were higher than those in adjacent tissues [7.35%(10/136)，18.38%(25/136)], with significant differences (χ2=109.846, 46.923, all P<0.05). The positive expression rates of PRDX4 and GRAMD1A in HCC patients with TNM stage III+IV, low tissue differentiation, multiple tumors, and HBsAg positive were higher than those in HCC patients with TNM stage I+II, high/medium tissue differentiation, fewer tumors, and HBsAg negative (χ2=12.273，16.359，10.004，5.485；23.217，24.461，18.651，8.594， all P<0.05). The 3-year survival rate of patients with PRDX4 positive expression [43.62%（41/94）] in HCC tissue was lower than that of patients with PRDX4 negative expression [73.81%（31/42）], the 3-year survival rate of GRAMD1A positive expression patients [46.25%（37/80）] was lower than that of GRAMD1A negative expression patients [62.50%（35/56）], and the differences were statistically significant (χ2=12.965, 7.475, all P<0.05). TNM staging, tumor number, HBsAg, PRDX4, and GRAMD1A expression were independent risk factors for mortality in HCC patients (P<0.05). Conclusion The positive rates of PRDX4 and GRAMD1A were increased in HCC tissues, and they were closely related to the poor prognosis of patients. Both of them may be used as biomarkers for diagnosis and prognosis evaluation of HCC.

参考文献/References:

[1] 吴良银, 李文丽, 刘俊. 肝细胞癌患者生存预后相关长链非编码RNA(LncRNA) 的生物信息学分析[J].现代检验医学杂志, 2019, 34(4): 18-21. WU Liangyin, LI Wenli, LIU Jun. Bioinformatics analysis of long-chain non-coding RNA related to survival and prognosis in patients with hepatocellular carcinoma [J]. Journal of Modern Laboratory Medicine,2019, 34(4): 18-21.
[2] 高云飞, 高凤成, 李清峰, 等. 原发性肝细胞癌患者TACE 治疗前后血清血小板源性生长因子-BB 水平变化及其临床意义[J]. 现代检验医学杂志, 2019,34(6): 73-76. GAO Yunfei, GAO Fengcheng, LI Qingfeng, et al. Changes of serum platelet-derived growth factor-BB level before and after TACE treatment in patients with primary hepatocellular carcinoma and its clinical significance [J]. Journal of Modern Laboratory Medicine, 2019, 34(6): 73-76.
[3] GILLES H, GARBUTT T, LANDRUM J. Hepatocellular Carcinoma [J]. Critical Care Nursing Clinics of North America, 2022, 34(3): 289-301.
[4] JAIN P, DVORKIN-GHEVA A, MOLLEN E, et al. NOX4 links metabolic regulation in pancreatic cancer to endoplasmic reticulum redox vulnerability and dependence on PRDX4[J]. Science Advances, 2021,7(19): eabf7114.
[5] PARK S Y, LEE Y J, PARK J, et al. PRDX4 overexpression is associated with poor prognosis in gastric cancer[J]. Oncology Letters, 2020, 19(5): 3522-3530.
[6] 朱涛, 王伟, 吴和刚. 胃癌组织中FOXP1 和FOXQ1的表达水平与临床病理特征及预后关系[J]. 现代检验医学杂志, 2021, 36(4): 68-73. ZHU Tao, WANG Wei, WU Hegang. Expression of FOXP1 and FOXQ1 in gastric cancer and their relationship with clinicopathological features and prognosis[J]. Journal of Modern Laboratory Medicine,2021, 36(4): 68-73.
[7] 章志诚. GRAMD1A 在肾细胞癌中的作用及初步机制研究[D]. 南昌: 南昌大学, 2023. ZHANG Zhicheng. Study on the role and preliminary mechanism of GRAMD1A in renal cell carcinoma[D].Nanchang: Nanchang University, 2023.
[8] 鲁迪. 过氧化物酶6(Peroxiredoxin6) 在肝细胞肝癌中的表达和作用机制研究[D]. 杭州: 浙江大学, 2016. LU Di. The expression and functional mechanism of peroxiredoxin 6 in hepatocellular carcinoma[D].Hanzhou: Zhejiang University,2017.
[9] 张竞, 涂康生, 周振宇, 等. GRAMD4 在肝细胞癌中的表达及临床意义[J]. 细胞与分子免疫学杂志,2013, 29(2): 190-193. ZHANG Jing, TU Kangsheng, ZHOU Zhenyu, et al. Expression and clinicopathological significance of GRAMD4 in hepatocellular carcinoma [J]. Chinese Journal of Cellular and Molecular Immunology, 2013,29(2): 190-193.
[10] 中华人民共和国国家卫生健康委员会医药行政司.中国原发性肝癌诊疗指南(2019 版)[J]. 中华肝脏病杂志, 2020, 28(2): 112-128. Department of Medical Administration, National Health Commission of the People’s Republic of China . Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition) [J]. Chinese Journal of Hepatology, 2020, 28(2): 112-128.
[11] BROWN Z J, TSILIMIGRAS D I, RUFF S M, et al. Management of hepatocellular carcinoma: a review[J].JAMA Surgery, 2023, 158(4): 410-420.
[12] 王路, 叶莎, 韩霞, 等. 循环外泌体miRNA 检测对肝细胞癌临床诊断效能的Meta 分析[J]. 现代检验医学杂志, 2022, 37(4): 59-63. WANG Lu, YE Sha, HAN Xia, et al. Meta-Analysis of the diagnostic value of circulating exosomes miRNA detection for hepatocellular carcinoma[J]. Journal of Modern Laboratory Medicine, 2022, 37(4): 59-63.
[13] CHEN Liangyuan, HUANG Chunli, YANG Xiaojun,et al. Prognostic roles of mRNA expression of peroxiredoxins in lung cancer[J]. Onco Targets and Therapy, 2018, 11: 8381-8388.
[14] JIA Wenqiao, CHEN Pengxiang, CHENG Yufeng. PRDX4 and its roles in various cancers[J]. Technology in Cancer Research & Treatment, 2019, 18:1533033819864313.
[15] MIZUTANI K, GUO X, SHIOYA A, et al. The impact of PRDX4 and the EGFR mutation status on cellular proliferation in lung adenocarcinoma[J]. International Journal of Medical Science, 2019, 16(9): 1199-1206.
[16] JEONG S H, KIM R B, PARK S Y, et al. Nomogram for predicting gastric cancer recurrence using biomarker gene expression[J]. European Journal of Surgical Oncology, 2020, 46(1): 195-201.
[17] LIANG Feng, WANG Shuang, GUO Yu, et al. Proteome profiling of endogenous and potential S-nitrosylation in colorectal cancer[J]. Frontiers in Endocrinology(Lausanne), 2023, 14: 1153719.
[18] GUO Xin, NOGUCHI H, ISHII N, et al. The association of peroxiredoxin 4 with the initiation and progression of hepatocellular carcinoma[J].Antioxidants & Redox Signaling, 2019, 30(10): 1271-1284.
[19] SONG Xiuli, WANG Shihao, GU Bin, et al. Production and characterization of a monoclonal antibody against GRAM domain-containing protein 1A[J]. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy,2014, 33(4): 246-253.
[20] FU Binsheng, MENG Wei, ZHAO Hui, et al. GRAM domain-containing protein 1A (GRAMD1A) promotes the expansion of hepatocellular carcinoma stem cell and hepatocellular carcinoma growth through STAT5[J].Scientific Reports, 2016, 6: 31963.
[21] LUO Zongjiang, LU Libai, TANG Qianli, et al. CircCAMSAP1 promotes hepatocellular carcinoma progression through miR-1294/GRAMD1A pathway[J].Journal of Cellular and Molecular Medicine, 2021,25(8): 3793-3802.

相似文献/References:

[1]邓旭,王晓亮.肝细胞癌患者血清趋化因子CXCR12和SA的表达及临床意义[J].现代检验医学杂志,2015,30(06):49.[doi:10.3969/j.issn.1671-7414.2015.06.014]
　DENG Xu,WANG Xiao-liang.Expression and Clinical Significance of Serum CXCR12 and SA in Patients with Hepatocarcinoma[J].Journal of Modern Laboratory Medicine,2015,30(03):49.[doi:10.3969/j.issn.1671-7414.2015.06.014]
[2]毛丽萍,何义民,韩 刚,等.血浆Dickkopf同源物1检测对肝细胞癌的诊断价值[J].现代检验医学杂志,2016,31(05):62.[doi:10.3969/j.issn.1671-7414.2016.05.016]
　MAO Li-ping,HE Yi-min,HAN Gang,et al.Diagnosis Value of Detecting Plasma Dickkopf-1 Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2016,31(03):62.[doi:10.3969/j.issn.1671-7414.2016.05.016]
[3]阮瑞杨,陈修荣,赵世元.抗EZH2自身抗体IgG在肝癌患者血清中的表达及意义[J].现代检验医学杂志,2017,32(02):72.[doi:10.3969/j.issn.1671-7414.2017.02.019]
　RUAN Rui-yang,CHEN Xiu-rong,ZHAO Shi-yuan.Expression and Significance of Anti EZH2 Autoantibodies IgG in Hepatocellular Carcinoma Patient's Serum Samples[J].Journal of Modern Laboratory Medicine,2017,32(03):72.[doi:10.3969/j.issn.1671-7414.2017.02.019]
[4]隆绍平,邓世群,赵世元.PTPN12蛋白表达下调与原发性肝细胞癌患者复发和预后关系研究[J].现代检验医学杂志,2018,33(01):86.[doi:10.3969/j.issn.1671-7414.2018.01.001]
　LONG Shao-ping,DENG Shi-qun,ZHAO Shi-yuan.Association between Downregulation of PTPN12 Protein and Recurrence and Prognosis in Patients with Primary Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(03):86.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[5]毛丽萍,王跃国,王 健,等.CMIA法测定血清DCP与AFP对肝细胞癌的诊断价值[J].现代检验医学杂志,2018,33(06):38.[doi:10.3969/j.issn.1671-7414.2018.06.010]
　MAO Li-ping,WANG Yue-guo,WANG Jian,et al.Diagnostic Value of the Serum DCP and AFP Determined by CMIA in Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(03):38.[doi:10.3969/j.issn.1671-7414.2018.06.010]
[6]吴良银a,李文丽b,刘 俊a.肝细胞癌患者生存预后相关长链非编码RNA(LncRNA)的生物信息学分析[J].现代检验医学杂志,2019,34(04):18.[doi:10.3969/j.issn.1671-7414.2019.04.005]
　WU Liang-yina,LI Wen-lib,LIU Juna.Bioinformatics Analysis of Long-Chain Non-Coding RNA Related to Survival and Prognosis in Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2019,34(03):18.[doi:10.3969/j.issn.1671-7414.2019.04.005]
[7]吴良银a,李文丽b,刘　俊b.基于GEO数据的病毒相关性肝癌潜在生物基因标志物的筛选及生物信息学分析[J].现代检验医学杂志,2021,36(06):106.[doi:10.3969/j.issn.1671-7414.2021.06.022]
　WU Liang-yin,LI Wen-li,LIU Jun.Screening and Bioinformatics Analysis of Potential Biomarkers for Virus-associated Hepatocellular Carcinoma Based on GEO Data[J].Journal of Modern Laboratory Medicine,2021,36(03):106.[doi:10.3969/j.issn.1671-7414.2021.06.022]
[8]陈 偲,李忠辉a,王 颖b.miR-198 通过靶向ZEB2 调控EMT 过程抑制肝癌细胞增殖和迁移的机制研究[J].现代检验医学杂志,2022,37(04):23.[doi:10.3969/j.issn.1671-7414.2022.04.005]
　CHEN Si,LI Zhong-huia,WANG Yingb.Study on the Mechanism of miR-198 Inhibiting the Proliferation and Migration of Hepatoma Cells by Regulating EMT Process by Targeting ZEB2[J].Journal of Modern Laboratory Medicine,2022,37(03):23.[doi:10.3969/j.issn.1671-7414.2022.04.005]
[9]王 路,叶 莎,韩 霞,等.循环外泌体miRNA 检测对肝细胞癌临床诊断效能的Meta 分析[J].现代检验医学杂志,2022,37(04):59.[doi:10.3969/j.issn.1671-7414.2021.04.012]
　WANG Lu,YE Sha,HAN Xia,et al.Meta-Analysis of the Diagnostic Value of Circulating Exosomes miRNA Detection for Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2022,37(03):59.[doi:10.3969/j.issn.1671-7414.2021.04.012]
[10]时晓晓a,董 翔a,于若卉b,等.miR-203a-3p 靶向GLS1 调控HCC 细胞增殖、迁移、侵袭的机制研究[J].现代检验医学杂志,2022,37(05):86.[doi:10.3969/j.issn.1671-7414.2022.05.018]
　SHI Xiao-xiaoa,DONG Xianga,YU Ruo-huib,et al.Mechanism of miR-203a-3p Targeting GLS1 to Regulate the Proliferation, Migration and Invasion of HCC Cells[J].Journal of Modern Laboratory Medicine,2022,37(03):86.[doi:10.3969/j.issn.1671-7414.2022.05.018]

备注/Memo

备注/Memo:
作者简介：赵倩（1989-），女，本科，中级职称，研究方向：临床医学检验，E-mail：yenh3sft@163.com。
更新日期/Last Update: 2024-05-15